Curis, Inc. (NASDAQ:CRIS) shareholders would be excited to see that the share price has had a great month, posting a 75% gain and recovering from prior weakness. Not all shareholders will be feeling ...
LEXINGTON, Mass., Nov. 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and ...
Curis, a microcap biotech company, is focusing on the development of cancer drugs, currently supporting six drug trials with a burn rate of over $30 million per year. Despite a recent direct offering ...
Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets -- ...
Good afternoon, ladies and gentlemen, and welcome to the Curis Third Quarter 2025 Business Update Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 6, 2025. I ...
LEXINGTON, Mass., July 2, 2025 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule ...
Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., Nov. 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback